E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
female patients with repetitive implantation failures during previous IVF/ICSI-cycles |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To show that the efficacy of LeukoNorm CytoChemia® applied as supportive immunotherapy within IVF/ICSI-treatment is superior to placebo with respect to an increased pregnancy rate |
|
E.2.2 | Secondary objectives of the trial |
To investigate the safety and tolerability of LeukoNorm CytoChemia® injection within a therapy scheme of 10 intra-muscular injections |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
· woman aged 18 to 39 years; · patients with a history of not less than 2 but not more than 3 previous failed IVF/ICSI-cycles (i.e. no constantly high serum-hCG and/or no clinical evidence for at least one embryo sac, determined by transvaginal sonography), with at least 4 morphologically good-looking embryos of the categories A and B according to Steer et al. · stimulation according to the long GnRH-agonist protocol or according to the GnRH-antagonist protocol (for details refer to section 9.5.1.1) · written informed consent obtained. A complete list of all inclusion criteria is given in the protocol section 9.3.2. |
|
E.4 | Principal exclusion criteria |
· patients with known or suspected uterine malformation · patients with known or suspected endometriosis class III and IV, according to rAFS-criteria · known or suspected numerical and/or structural chromosomal anomalies in one or both partners
· usage of cryopreserved unfertilized oocytes, oocytes at the pronuclear stage, or embryos · previous low response (< 5 oocytes retrieved) in a gonadotropin stimulation GnRH agonist or anatagonist protocol for IVF or ICSI · clinical significant findings of a severe autoimmune disease, respectively clinical manifested severe autoimmune disease (e.g. rheumatoid arthritis, multiple sclerosis) and/or currently treated autoimmune disease · any kind of organ transplantation · patients receiving immunosuppressive therapy, including systemic corticosteroids, or cytotoxic agents A complete list of all exclusion criteria is given in the protocol section 9.3.3. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable will be the rate of successful pregnancies, measured by clinical methods (transvaginal sonography). Thereby a positive heart activity within at least one intrauterine embryonic sac will be regarded as successful pregnancy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study = date of last visit of last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |